| TRV |
Report |
Core EPS (Q2 2026) |
MISS |
pred ~$4.65 vs. cons $5.38 |
MEDIUM |
| TRV |
Report |
CAT Losses pretax (Q2 2026) |
MISS |
pred ~$1.30B vs. cons $1.05B |
MEDIUM |
| TRV |
Report |
Underlying Combined Ratio (Q2 2026) |
BEAT |
pred ~84.5% vs. cons 85.6% |
MEDIUM |
| TRV |
Guide |
Q3 NII after-tax (Q3 2026) |
BETTER |
guide ~$840M vs. cons $806M |
HIGH |
| TRV |
Guide |
FY 2026 Expense Ratio |
UNCHANGED |
guide ~28.5% vs. cons ~28.5% |
HIGH |
| TRV |
Guide |
Casualty Reserve Posture (qualitative) |
UNCHANGED |
Reiterate uncertainty provision; no adverse development |
MEDIUM |
| TRV |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
MEDIUM |
| TRV |
Return |
5-day cumulative residual |
-5.0% (FADE) |
FADE — estimate cuts on CAT miss, shorts hold, no squeeze catalyst |
MEDIUM |